Cross Country Healthcare Confirms Acquisition by Knox Lane Amidst Significant Q1 Revenue Decline and Widening Losses
CCRN sits 76% above its 52-week low of $7.43 on elevated volume (10× avg).
Summary
Cross Country Healthcare's Q1 2026 results show a sharp revenue decline and increased losses, providing context for the previously announced definitive merger agreement with Knox Lane for $13.25 per share.
Key Events · M&A and Partnerships · CCRN
-
Definitive Merger Confirmed
The company reaffirmed its definitive agreement to be acquired by Knox Lane for $13.25 per share, a transaction that will result in the company's delisting.
-
Significant Q1 Revenue Decline
Revenue for the first quarter of 2026 decreased by 17.8% year-over-year to $241.1 million, primarily due to volume declines in both Nurse and Allied Staffing and Physician Staffing segments.
-
Widening Net Loss
The company reported a net loss of $4.3 million for Q1 2026, a substantial increase from a net loss of $0.5 million in the prior-year period.
-
Increased Operating Losses
Loss from operations worsened to $4.155 million in Q1 2026, compared to $0.977 million in Q1 2025.
Analysis · CCRN · Trade & Services
This 10-Q filing confirms the definitive merger agreement with Knox Lane for $13.25 per share, a transaction previously announced on May 6, 2026. The filing also reveals a substantial deterioration in Q1 2026 financial performance, with revenue decreasing by 17.8% year-over-year to $241.1 million and net loss widening significantly from $0.5 million to $4.3 million. These poor results provide a clear fundamental backdrop for the company's decision to accept the acquisition offer, offering shareholders an exit at a premium to the current market price despite the challenging operational environment. The merger is expected to lead to the company's delisting from Nasdaq.
At the time of this filing, CCRN was trading at $13.05 on NASDAQ in the Trade & Services sector, with a market capitalization of approximately $423.1M. The 52-week trading range was $7.43 to $14.99. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.